View |
|
BR-824
|
Lutropin Alfa
|
Luveris
|
75 IU (equivalent to 3.7 mcg/mL)
|
Lyophilized Powder For Injection (SC)
|
-
|
Merck Serono SA
|
Switzerland
|
-
|
30 March 2021
|
13 July 2026
|
View |
|
BR-825
|
Epoetin Alfa
|
Renogen
|
2000 IU/mL
|
Solution For Injection (IV/SC)
|
-
|
Shenzhen Sciprogen Bio-Pharmaceutical Co., Ltd.
|
China
|
Renewal
|
30 March 2021
|
18 April 2026
|
View |
|
BR-826
|
Diphtheria, Tetanus, Pertussis (Whole-Cell), Recombinant Hepatitis B, Haemophilus Influenzae Type B Combined Vaccine
|
Easyfive TT
|
[see reverse for formulation]
|
Suspension for Injection (IM)
|
Vaccine
|
Panacea Biotec Limited (Vaccine Division)
|
India
|
Automatic Renewal
|
07 August 2021
|
04 August 2026
|
View |
|
BR-827
|
Typhoid Polysaccharide Vaccine
|
Typbar
|
25 mcg/0.5 mL
|
Solution for Injection (IM)
|
-
|
Bharat Biotech International Ltd.
|
India
|
-
|
18 March 2022
|
15 August 2026
|
View |
|
BR-828
|
Typhoid Polysaccharide Vaccine
|
Typbar
|
Formulation: Each dose (0.5 mL) contains: Purified Vi-capsular polysaccharide of Salmonella typhi (Ty2 strain) ................25 mcg
|
Solution for Injection (IM)
|
-
|
Bharat Biotech International Ltd.
|
India
|
-
|
18 March 2022
|
15 August 2026
|
View |
|
BR-829
|
Follitropin Alfa
|
Gonal-F
|
450 IU/0.75 mL (33mcg/0.75mL)
|
Solution For Injection (SC)
|
Recombinant Follicle Stimulating Hormone
|
Merck Serono S.p.A.
|
Italy
|
Renewal
|
30 March 2021
|
26 August 2026
|
View |
|
BR-830
|
Gonal-F
|
Follitropin Alfa
|
300 IU/0.5 mL (22 mcg/0.5 mL)
|
Solution For Injection (Sc)
|
-
|
Merck Serono S.p.A.
|
Italy
|
-
|
17 May 2021
|
26 August 2026
|
View |
|
BR-831
|
Follitropin Alfa
|
Gonal-F
|
900 IU/1.5 mL (66 mcg/1.5 mL)
|
Solution For Injection (SC)
|
-
|
Merck Serono S.p.A.
|
Italy
|
-
|
29 June 2021
|
05 September 2026
|
View |
|
BR-838
|
Denosumab
|
Prolia
|
60 mg/ mL
|
Solution For Injection (Sc)
|
-
|
Amgen Manufacturing Limited
|
United States of America
|
Initial
|
05 October 2020
|
22 December 2024
|
View |
|
BR-839
|
Measles and Rubella Vaccine (Live)
|
SII MR VAC
|
NLT 1000 CCID50/0.5 mL
|
Lyophilized Powder For Injection (S.C.)
|
-
|
Serum Institute of India Pvt. Ltd.
|
India
|
Initial (Variation)
|
05 December 2022
|
05 December 2027
|
View |
|
BR-846
|
Interferon-Beta 1B
|
Betaferon
|
250mcg (8million/ IU/mL)
|
Lyophilized powder for injection (SC)
|
Immunostimulant
|
Bayer Pharma AG
|
Germany
|
Renewal
|
07 March 2022
|
15 February 2027
|
View |
|
BR-851
|
Bacillus Calmette-Guerin Vaccine (Live, Attenuated)
|
SII-Onco-BCG
|
40 mg/mL
|
Lyophilized Powder for Intravesical Instillation
|
-
|
Serum Institute of India Pvt. Ltd.
|
India
|
Initial [Variation]
|
18 December 2023
|
18 December 2028
|
View |
|
BR-853
|
Denosumab
|
Xgeva
|
70 mg per mL
|
Solution For Injection (Sc)
|
-
|
Amgen Manufacturing Limited
|
U.S.A
|
Initial
|
30 August 2023
|
30 August 2028
|
View |
|
BR-856
|
Enoxaparin Sodium
|
Olxarin
|
2,000 IU/0.2 mL (20mg/0.2 mL)
|
Solution For Injection (Sc)
|
-
|
Hangzhou Jiuyuan Gene Engineering Co., Ltd.
|
China
|
Initial
|
04 August 2021
|
04 April 2025
|
View |
|
BR-857
|
Enoxaparin Sodium
|
Olxarin
|
8,000 IU/0.8mL (80mg/0.8mL)
|
Solution For Injection (Sc)
|
-
|
Hangzhou Jiuyuan Gene Engineering Co., Ltd.
|
China
|
Initial
|
04 August 2021
|
04 April 2025
|
View |
|
BR-858
|
Enoxaparin Sodium
|
Olxarin
|
6,000 IU/0.6mL (60 mg/0.6mL)
|
Solution For Injection (Sc)
|
-
|
Hangzhou Jiuyuan Gene Engineering Co., Ltd.
|
China
|
Initial
|
04 August 2021
|
04 April 2025
|
View |
|
BR-859
|
Recombinant Human Erythropoietin Alfa
|
Eposis
|
2000 I.U./0.5mL
|
Solution For Injection (I.V./S.C.)
|
Hematopoietic Growth Factor
|
Daewoong Pharmaceutical Co., Ltd.
|
Korea
|
Renewal
|
21 April 2022
|
16 April 2027
|
View |
|
BR-860
|
Enoxaparin Sodium
|
Olxarin
|
4,000 IU/0.4mL (40 mg/0.4 mL)
|
Solution For Injection (Sc)
|
-
|
Hangzhou Jiuyuan Gene Engineering Co., Ltd.
|
China
|
Initial
|
04 August 2021
|
17 April 2025
|
View |
BR-862_PI_01.pdf
|
BR-862
|
Belimumab
|
Benlysta
|
120 mg vial Each vial contains a sufficient amount of belimumab to deliver 120 mg in 1.5 mL when reconstituted as recommended with sterile Water for Injections. After reconstitution, each mL of solution contains 80 mg belimumab.
400 mg vial Each vial contains a sufficient amount of belimumab to deliver 400 mg in 5.0 mL when reconstituted as recommended with sterile Water for Injections. After reconstitution, each mL of solution contains 80 mg belimumab.
|
Powder for Solution for Injection (IV Infusion)
|
-
|
GlaxoSmithKline Manufacturing S.P.A.
|
Italy
|
Initial
|
12 October 2021
|
17 April 2025
|
View |
|
BR-868
|
Recombinant Human Erythropoietin Alfa
|
Eposis
|
10,000 I.U./mL
|
Solution For Injection (I.V./S.C.)
|
Hematopoietic Growth Factor
|
Daewoong Pharmaceutical Co., Ltd.
|
Korea
|
Automatic Renewal
|
01 April 2022
|
17 May 2027
|